Gene · 580
Papers4,139
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,021 to 1,040 of 4,139
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Radon and Lung Cancer: Current Trends and Future Perspectives. | Cancers (Basel) | 2022 | 35804914 | PubTator, text mining | PubMed |
| Strand annealing and motor driven activities of SMARCAL1 and ZRANB3 are stimulated by RAD51 and the paralog complex. | Nucleic Acids Res | 2022 | 35801922 | PubTator, text mining | PubMed |
| Homologous recombination repair deficient prostate cancer represents an immunologically distinct subtype. | Oncoimmunology | 2022 | 35800157 | PubTator, text mining | PubMed |
| Clinical implications and practical considerations for poly-ADP-ribose polymerase inhibitors as a new horizon for the management of urothelial carcinoma of the bladder. | Investig Clin Urol | 2022 | 35796137 | PubTator, text mining | PubMed |
| Current Status of Human Papillomavirus Infection and Cervical Cancer in the Philippines. | Front Med (Lausanne) | 2022 | 35795639 | PubTator, text mining | PubMed |
| Long noncoding RNA Smyca coactivates TGF-β/Smad and Myc pathways to drive tumor progression. | J Hematol Oncol | 2022 | 35794621 | PubTator, text mining | PubMed |
| Homologous Recombination Deficiency in Ovarian, Breast, Colorectal, Pancreatic, Non-Small Cell Lung and Prostate Cancers, and the Mechanisms of Resistance to PARP Inhibitors. | Front Oncol | 2022 | 35785170 | PubTator, text mining | PubMed |
| Modern Breast Cancer Surgery 1st Central-Eastern European Professional Consensus Statement on Breast Cancer. | Pathol Oncol Res | 2022 | 35783360 | PubTator, text mining | PubMed |
| The Great Majority of Homologous Recombination Repair-Deficient Tumors Are Accounted for by Established Causes. | Front Genet | 2022 | 35783256 | PubTator, text mining | PubMed |
| Homologous recombination repair deficiency (HRD) testing in newly diagnosed advanced-stage epithelial ovarian cancer: A Belgian expert opinion. | Facts Views Vis Obgyn | 2022 | 35781107 | PubTator, text mining | PubMed |
| The immune microenvironment features and response to immunotherapy in EBV-associated lymphoepithelioma-like cholangiocarcinoma. | Hepatol Int | 2022 | 35780451 | PubTator, text mining | PubMed |
| Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D. | Breast | 2022 | 35772246 | PubTator, text mining | PubMed |
| PARP Inhibitor Insensitivity to BRCA1/2 Monoallelic Mutations in Microsatellite Instability-High Cancers. | JCO Precis Oncol | 2022 | 35772050 | PubTator, text mining | PubMed |
| Mutations of 1p genes do not consistently abrogate tumor suppressor functions in 1p-intact neuroblastoma. | BMC Cancer | 2022 | 35768791 | PubTator, text mining | PubMed |
| PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer. | NPJ Precis Oncol | 2022 | 35768576 | PubTator, text mining | PubMed |
| Pathogenicity Reclassification of Genetic Variants Related to Early-Onset Breast Cancer among Women of Mongoloid Origin. | Asian Pac J Cancer Prev | 2022 | 35763645 | PubTator, text mining | PubMed |
| The lncRNA PRINS-miRNA-mRNA Axis Gene Expression Profile as a Circulating Biomarker Panel in Psoriasis. | Mol Diagn Ther | 2022 | 35761165 | PubTator, text mining | PubMed |
| The Chromatin Landscape Channels DNA Double-Strand Breaks to Distinct Repair Pathways. | Front Cell Dev Biol | 2022 | 35757003 | PubTator, text mining | PubMed |
| Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved Test. | Cells | 2022 | 35741030 | PubTator, text mining | PubMed |
| The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair. | Cancers (Basel) | 2022 | 35740616 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/580/papers?page=52